Evidence map›Paper›PMID 39713326›Full record

ArticlebioRxiv : the preprint server for biology2024

THE FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycle.

Taylar Hammond, Jong Bin Choi, Miles W Membreño, Janos Demeter, Roy Ng, Debadrita Bhattacharya, Thuyen N Nguyen, Griffin G Hartmann, Carine Bossard, Jan M Skotheim and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Taylar Hammond
Jong Bin Choi
Miles W Membreño
Janos Demeter
Roy Ng
Debadrita Bhattacharya
Thuyen N Nguyen
Griffin G Hartmann
Carine Bossard
Jan M Skotheim
Peter K Jackson
Anca Pasca
Seth M Rubin

Funding

Project 3: Defining and targeting mechanisms of E2F transcription factor regulationP01CA254867 · NCI · STANFORD UNIVERSITY · PI PETER Kent JACKSON · 2022 to 2026
$8.9M
NCI NIH HHS P01 CA254867
6 · The paper itself

Abstract

A growing number of therapies are being developed to target the cell cycle machinery for the treatment of cancer and other human diseases. Consequently, a greater understanding of the factors regulating cell cycle progression becomes essential to help enhance the response to these new therapies. Here, using data from the Cancer Dependency Map, we identified the poorly-studied factor FAM53C as a new regulator of cell cycle progression. We found that FAM53C is critical for this cell cycle transition and that it acts upstream of the CyclinD-CDK4/6-RB axis in the regulation of the G1/S transition. By mass spectrometry, biochemical, and cellular assays, we identified and validated DYRK1A as a cell cycle kinase that is inhibited by and directly interacts with FAM53C. DYRK1A kinase inhibition rescues the G1 arrest induced by FAM53C knock-down. Consistent with the role for FAM53C identified in cells in culture,

Identifiers

PMID39713326
PMCPMC11661141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.